RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jorge Duconge to Humans

Back to Details
This is a "connection" page, showing publications Jorge Duconge has written about Humans.
Jorge Duconge
Connection Strength
1.088
Humans
  1. Monero-Paredes M, Feliu-Maldonado R, Carrasquillo-Carrion K, Gonzalez P, Rogozin IB, Roche-Lima A, Duconge J. Non-Random Enrichment of Single-Nucleotide Polymorphisms Associated with Clopidogrel Resistance within Risk Loci Linked to the Severity of Underlying Cardiovascular Diseases: The Role of Admixture. Genes (Basel). 2023 09 17; 14(9).
    View in: PubMed
    Score: 0.046
  2. Duconge J, Santiago E, Hernandez-Suarez DF, Moner? M, L?pez-Reyes A, Rosario M, Renta JY, Gonz?lez P, Ileana Fern?ndez-Morales L, Antonio V?lez-Figueroa L, Arce O, Mar?n-Maldonado F, Nu?ez H, Melin K, Scott SA, Rua?o G. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci. 2021 11; 14(6):2254-2266.
    View in: PubMed
    Score: 0.040
  3. Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 08 18; 35(4).
    View in: PubMed
    Score: 0.037
  4. Hernandez-Suarez DF, Melin K, Marin-Maldonado F, Nunez HJ, Gonzalez AF, Gonzalez-Sepulveda L, Rivas-Tumanyan S, Naik H, Rua?o G, Scott SA, Duconge J. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020 08 06; 10(8):e038936.
    View in: PubMed
    Score: 0.037
  5. Claudio-Campos K, Moner?-Paredes M, Hern?ndez E, Renta J, Duconge J. Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. 2019 08; 20(12):891-902.
    View in: PubMed
    Score: 0.034
  6. Claudio-Campos KI, Gonz?lez-Santiago P, Renta JY, Rodr?guez J, Carrasquillo K, Gaedigk A, Roche A, Ducong? J. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics. 2019 01; 20(1):3-8.
    View in: PubMed
    Score: 0.033
  7. Duconge J, Rua?o G. Preventing the exacerbation of health disparities by iatrogenic pharmacogenomic applications: lessons from warfarin. Pharmacogenomics. 2018 07 01; 19(11):875-881.
    View in: PubMed
    Score: 0.032
  8. Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nu?ez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6).
    View in: PubMed
    Score: 0.032
  9. Hernandez-Suarez DF, N??ez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 03 28; 33(1):49-55.
    View in: PubMed
    Score: 0.031
  10. Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241.
    View in: PubMed
    Score: 0.030
  11. Jim?nez-Ram?rez FJ, Castro LM, Ortiz C, Concepci?n J, Renta JY, Morales-Borges RH, Miranda-Massari JR, Duconge J. Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metab Pers Ther. 2017 03 01; 32(1):23-32.
    View in: PubMed
    Score: 0.029
  12. Duconge J, Hernandez-Suarez DF. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. Curr Clin Pharmacol. 2017; 12(1):11-17.
    View in: PubMed
    Score: 0.029
  13. Duconge J, Rua?o G. Admixture and ethno-specific alleles: missing links for global pharmacogenomics. Pharmacogenomics. 2016 09; 17(14):1479-82.
    View in: PubMed
    Score: 0.028
  14. Duconge J, Ramos AS, Claudio-Campos K, Rivera-Miranda G, Berm?dez-Bosch L, Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Rua?o G. A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One. 2016; 11(1):e0145480.
    View in: PubMed
    Score: 0.027
  15. Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, Garc?a R, Hern?ndez G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther. 2015 Dec; 30(4):239-49.
    View in: PubMed
    Score: 0.027
  16. Duconge J, Rua?o G. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015; 16(15):1685-8.
    View in: PubMed
    Score: 0.026
  17. Duconge J, Cadilla CL, Seip RL, Rua?o G. Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J. 2015 Sep; 34(3):175-7.
    View in: PubMed
    Score: 0.026
  18. Valent?n II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Rua?o G, Duconge J. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014 Sep; 33(3):97-104.
    View in: PubMed
    Score: 0.024
  19. Duconge J, Cadilla CL. CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters? Biomark Med. 2013 Dec; 7(6):913-4.
    View in: PubMed
    Score: 0.023
  20. Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K, Vergara C, Rua?o G, Duconge J. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012 Dec; 13(16):1937-50.
    View in: PubMed
    Score: 0.022
  21. Duconge J, Rua?o G. 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics. 2012 Jul; 13(10):1097-100.
    View in: PubMed
    Score: 0.021
  22. Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Rua?o G, Duconge J. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. 2012 Feb; 46(2):208-18.
    View in: PubMed
    Score: 0.020
  23. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011 Nov; 6(4):260-73.
    View in: PubMed
    Score: 0.020
  24. Rodr?guez-V?lez R, Ortiz-Rivera OJ, Bower B, Gorowski K, Windemuth A, Villagra D, Kocherla M, Seip RL, D'Agostino D, Vergara C, Rua?o G, Duconge J. Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J. 2010 Dec; 29(4):402-8.
    View in: PubMed
    Score: 0.019
  25. Gonz?lez MJ, Miranda-Massari JR, Duconge J. Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later: comment on the article by Cabanillas. P R Health Sci J. 2010 Dec; 29(4):410-1; author reply 411-2.
    View in: PubMed
    Score: 0.019
  26. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5.
    View in: PubMed
    Score: 0.016
  27. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethn Dis. 2009; 19(4):479-80.
    View in: PubMed
    Score: 0.016
  28. Duconge J, Cadilla CL, Renta JY, Sil?n-Rivera P, Piovanetti P, Garc?a-Berdec?a R, Castro-Rosario LM, Monz?n S, V?lez L, Rosas G, Guerra JA, Santiago-Borrero PJ. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J. 2008 Dec; 27(4):357-8.
    View in: PubMed
    Score: 0.016
  29. Duconge J. Applying organ clearance concepts in a clinical setting. Am J Pharm Educ. 2008 Oct 15; 72(5):121.
    View in: PubMed
    Score: 0.016
  30. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008 Mar; 27(1):7-19.
    View in: PubMed
    Score: 0.016
  31. Ducong? J, Merino N, Alvarez D, Beausoleil I, Fern?ndez-S?nchez E, Rodr?guez L, Burt AD. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice. P R Health Sci J. 2008 Mar; 27(1):35-41.
    View in: PubMed
    Score: 0.016
  32. Duconge J, Miranda-Massari JR, Gonz?lez MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother. 2007 Jun; 41(6):1082-3.
    View in: PubMed
    Score: 0.015
  33. Duconge J. The case of biotech-derived product equivalence: much ado about nothing? Curr Clin Pharmacol. 2006 May; 1(2):147-56.
    View in: PubMed
    Score: 0.014
  34. Ducong? J, Rodr?guez-Vera L, Valenzuela C, Alvarez D, Ram?rez O, de la Luz-Hern?ndez KR, Rabeza-Leg?n EY, Casac? A, Fern?ndez-S?nchez E. Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factor after subcutaneous administration in rabbits. Eur J Pharm Biopharm. 2005 Oct; 61(3):142-8.
    View in: PubMed
    Score: 0.013
  35. Ducong? J, Fern?ndez-S?nchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos. 2004 May; 25(4):177-86.
    View in: PubMed
    Score: 0.012
  36. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Becquer MA, Fern?ndez-S?nchez E. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci. 2004 Feb; 21(2-3):261-70.
    View in: PubMed
    Score: 0.012
  37. Rodr?guez-Fern?ndez K, Reynaldo-Fern?ndez G, Reyes-Gonz?lez S, de Las Barreras C, Rodr?guez-Vera L, Vlaar C, Monbaliu JM, Stelzer T, Duconge J, Mangas-Sanjuan V. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. Biomed Pharmacother. 2024 Jan; 170:115977.
    View in: PubMed
    Score: 0.012
  38. Hernandez-Martinez V, Duconge J, Rua?o G. An Expiration Date for Pharmacogenetic Test Results and Prescribing Guidance? J Appl Lab Med. 2023 07 05; 8(4):826-830.
    View in: PubMed
    Score: 0.011
  39. Steiner HE, Carrion KC, Giles JB, Lima AR, Yee K, Sun X, Cavallari LH, Perera MA, Duconge J, Karnes JH. Local Ancestry-Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations. Clin Pharmacol Ther. 2023 03; 113(3):680-691.
    View in: PubMed
    Score: 0.011
  40. Morales-Borges RH, Gonzalez MJ, Duconge J, Minich DM. N-Acetyl Cysteine and Glutathione in Health and Cancer-Pharmacogenomics, Research, and Clinical Practice: Hypothesis and Review. Altern Ther Health Med. 2022 Oct; 28(7):169-177.
    View in: PubMed
    Score: 0.011
  41. Duconge J, Fern?ndez-S?nchez E, Mac?as A, Castillo R, Garcia I, Beausoleil I, Amador JF, Matheu J. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun; 27(2):101-5.
    View in: PubMed
    Score: 0.010
  42. Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194.
    View in: PubMed
    Score: 0.010
  43. Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hern?ndez-O'Farrill E, Vlaar CP, Dharmawardhane S. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer. Mol Cancer Ther. 2021 12; 20(12):2420-2432.
    View in: PubMed
    Score: 0.010
  44. Vald?s-Fern?ndez BN, Duconge J, Espino AM, Rua?o G. Personalized health and the coronavirus vaccines-Do?individual genetics matter? Bioessays. 2021 09; 43(9):e2100087.
    View in: PubMed
    Score: 0.010
  45. Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Rodrigues Botton M, Woodahl EL, Scott SA, Klein TE, Pratt VM, Daly AK, Gaedigk A. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021 09; 110(3):662-676.
    View in: PubMed
    Score: 0.010
  46. El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clin Transl Sci. 2021 01; 14(1):268-276.
    View in: PubMed
    Score: 0.009
  47. Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, Cavallari LH, Marcatto LR, Beasly MT, Perera MA, Limdi NA, Santos PCJL, Kimmel SE, Lubitz SA, Scott SA, Kawai VK, Jorgensen AL, Pirmohamed M. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2020 06; 107(6):1420-1433.
    View in: PubMed
    Score: 0.009
  48. Graydon JS, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A, Rodr?guez-Maldonado J, Duconge J, Rua?o G. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations. Biomark Med. 2019 06; 13(8):649-661.
    View in: PubMed
    Score: 0.008
  49. Melin K, Moon JY, Qi Q, Hernandez-Suarez DF, Duconge J, Hua S, Gonzalez S, Zeng D, Kaplan RC. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. Pharmacogenomics. 2019 01; 20(2):75-83.
    View in: PubMed
    Score: 0.008
  50. Encarnaci?n-Medina J, Rodr?guez-Cotto RI, Bloom-Oquendo J, Ortiz-Mart?nez MG, Duconge J, Jim?nez-V?lez B. Selective ATP-Binding Cassette Subfamily C Gene Expression and Proinflammatory Mediators Released by BEAS-2B after PM2.5, Budesonide, and Cotreated Exposures. Mediators Inflamm. 2017; 2017:6827194.
    View in: PubMed
    Score: 0.007
  51. C?spedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, Montan?-Jaime LK, Roblejo H, Fari?as H, Campos ML, Ram?rez R, Serrano V, Villagr?n CI, Pe?as-LLed? EM. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics. 2016 10; 17(15):1707-1724.
    View in: PubMed
    Score: 0.007
  52. Claudio-Campos K, Duconge J, Cadilla CL, Rua?o G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Ther. 2015 Jun; 30(2):87-105.
    View in: PubMed
    Score: 0.006
  53. Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Mart?nez V, Duconge J, Aponte A, Ricart CM. Metabolic Correction as a tool to improve diabetes type 2 management. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):54-9.
    View in: PubMed
    Score: 0.006
  54. Miranda-Massari JR, Gonz?lez MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo MZ, Jim?nez Ramirez FJ, Cintr?n K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, V?zquez A. [Metabolic correction: a biochemical option against diseases]. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):60-6.
    View in: PubMed
    Score: 0.006
  55. Gonz?lez MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jim?nez-Ram?rez FJ, Cintr?n K, Rodr?guez-G?mez JR, Rosario G, Ricart C, Santiago-Cornier JA, Zaragoza-Urdaz R, V?zquez A, Hickey S, Jabbar-Berdiel M, Riordan N, Ichim T, Santiago O, Alvarado G, Vora P. Metabolic correction: a functional biochemical mechanism against disease--Part 1: concept and historical background. P R Health Sci J. 2015 Mar; 34(1):3-8.
    View in: PubMed
    Score: 0.006
  56. Miranda-Massari JR, Gonz?lez MJ, Duconge J, Allende-Vigo MZ, Jim?nez-Ram?rez FJ, Hickey S, V?zquez A, Berdiel MJ, Cintr?n K, Rodr?guez-G?mez JR. Metabolic correction: a functional biochemical mechanism against disease--Part 2: mechanisms and benefits. P R Health Sci J. 2015 Mar; 34(1):9-13.
    View in: PubMed
    Score: 0.006
  57. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T, Quintero-Del-Rio AI, Ortiz N. The bio-energetic theory of carcinogenesis. Med Hypotheses. 2012 Oct; 79(4):433-9.
    View in: PubMed
    Score: 0.005
  58. Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Rua?o G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11.
    View in: PubMed
    Score: 0.005
  59. Seip RL, Duconge J, Rua?o G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010 May; 6(3):409-24.
    View in: PubMed
    Score: 0.005
  60. LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Rua?o G. Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med. 2008 Aug; 72(7):399-403.
    View in: PubMed
    Score: 0.004
  61. Garc?a-Santana MA, Duconge J, Sarmiento ME, Lanio-Ru?z ME, Becquer MA, Izquierdo L, Acosta-Dom?nguez A. Biodistribution of liposome-entrapped human gamma-globulin. Biopharm Drug Dispos. 2006 Sep; 27(6):275-83.
    View in: PubMed
    Score: 0.004
  62. Hern?ndez-Bernal F, Garc?a-Garc?a I, Gonz?lez-Delgado CA, Valenzuela-Silva C, Soto-Hern?ndez R, Ducong? J, Cervantes-Llano M, Blanco-Garc?s E, Rodr?guez V, Garc?a-Vega Y, Bello-Rivero I, Olivera-Ruano L, L?pez-Saura P. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos. 2005 May; 26(4):151-9.
    View in: PubMed
    Score: 0.003
  63. Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducong? J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D. 2004; 5(5):271-80.
    View in: PubMed
    Score: 0.003
  64. Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fern?ndez-S?nchez E. Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds. Biopharm Drug Dispos. 2002 Mar; 23(2):67-76.
    View in: PubMed
    Score: 0.003
  65. Morales AA, Ducong? J, Alvarez-Ruiz D, Becquer-Viart ML, N??ez-Gandolff G, Fern?ndez E, Caballero-Torres I, Iznaga-Escobar N. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol. 2000 Feb; 27(2):199-206.
    View in: PubMed
    Score: 0.002
  66. Morales AA, N??ez-Gandolff G, P?rez NP, V?liz BC, Caballero-Torres I, Ducong? J, Fern?ndez E, Crespo FZ, Veloso A, Iznaga-Escobar N. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. Nucl Med Biol. 1999 Aug; 26(6):717-23.
    View in: PubMed
    Score: 0.002
  67. Morales-Morales A, Ducong? J, Caballero-Torres I, N??ez-Gandolff G, Fern?ndez E, Iznaga-Escobar N. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol. 1999 Apr; 26(3):275-9.
    View in: PubMed
    Score: 0.002
  68. Iznaga Escobar N, Morales AM, Ducong? J, Torres IC, Fern?ndez E, G?mez JA. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol. 1998 Jan; 25(1):17-23.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support